Ox bile extract
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Ox bile extract
- Accession Number
- DB14016
- Description
- Not Available
- Type
- Biotech
- Groups
- Approved, Experimental, Investigational
- Synonyms
- Beef bile
- Bos bovis bile
- Bos taurus bile
- Bovine bile
- Fel tauri
- Ox bile
- Purified oxgall
- Sodium choleate
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
- Not Available
- Associated Conditions
- Cholecystopathy
- Chronic Constipation
- Dyspepsia
- Herpes Zoster
- Muscle Spasms
- Osteoarthritis (OA)
- Pancreatic Insufficiency
- Postoperative digestive insufficiency
- Prolonged Labour
- Sore Throat
- Digestion
- Gallstone formation
- Gastric acid deficiency
- Inflammatory disease of the pancreas
- Sinusitis following surgery or injury
- Associated Therapies
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAluminium phosphate The serum concentration of Ox bile extract can be decreased when it is combined with Aluminium phosphate. Aluminum chloride The serum concentration of Ox bile extract can be decreased when it is combined with Aluminum chloride. Aluminum chlorohydrate The serum concentration of Ox bile extract can be decreased when it is combined with Aluminum chlorohydrate. Aluminum hydroxide The serum concentration of Ox bile extract can be decreased when it is combined with Aluminum hydroxide. Aluminum sulfate The serum concentration of Ox bile extract can be decreased when it is combined with Aluminum sulfate. Bentonite The serum concentration of Ox bile extract can be decreased when it is combined with Bentonite. Bentoquatam The serum concentration of Ox bile extract can be decreased when it is combined with Bentoquatam. Cyproterone acetate The therapeutic efficacy of Ox bile extract can be decreased when used in combination with Cyproterone acetate. Desogestrel The therapeutic efficacy of Ox bile extract can be decreased when used in combination with Desogestrel. Dienogest The therapeutic efficacy of Ox bile extract can be decreased when used in combination with Dienogest. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Alka-pan Tablets Ox bile extract (35 mg) + Betaine hydrochloride (20 mg) + Bromelains (50 mg) + Pancrelipase (135 mg) + Papaya (125 mg) Tablet Oral Morter Healthsystem Not applicable Not applicable Canada 
Dygest Ox bile extract (75 mg) + Betaine hydrochloride (90 mg) + Pancrelipase (200 mg) + Papain (100 mg) + Peppermint (50 mg) + Pepsin (125 mg) Tablet Oral Creative Nutrition Canada Corp. 1987-12-31 2007-07-11 Canada Enzyme Tablets Ox bile extract (8.125 mg) + Betaine hydrochloride (65 mg) + Pancrelipase (100 mg) + Pancrelipase amylase (130 mg) + Papain (65 mg) + Pepsin (65 mg) Tablet Oral General Nutrition Canada Inc. 2001-10-20 2007-08-01 Canada Formule 1705 - Liq Ox bile extract (1.56 mg) + Magnesium sulfate (250 mg) Liquid Oral Bio Vita 1993-12-31 2003-07-16 Canada Laxo-lax Tab Ox bile extract (65 mg) + Frangula purshiana bark (97 mg) + Phenolphthalein (97 mg) Tablet Oral Les Aliments Nutri Source Inc. 1992-12-31 1997-08-11 Canada Pancreatin and Enzyme Formula - Tablet Ox bile extract (5 mg) + Bromelains (50 mg) + Pancrelipase (350 mg) + Pancrelipase lipase (50 mg) + Pepsin (100 mg) Tablet Oral Health Wise Nutrition Inc. 1997-08-15 2000-07-29 Canada Stozyme Ox bile extract (5.21 1/1001) + Dimethicone (5.21 1/1001) + Hemicellulase (10.42 1/1001) + Pancrelipase (36.46 1/1001) Tablet Oral Chunwoo Pharmaceutical Co., Ltd. 2019-10-19 Not applicable US 
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Stozyme Ox bile extract (5.21 1/1001) + Dimethicone (5.21 1/1001) + Hemicellulase (10.42 1/1001) + Pancrelipase (36.46 1/1001) Tablet Oral Chunwoo Pharmaceutical Co., Ltd. 2019-10-19 Not applicable US
Categories
- Drug Categories
- Classification
- Not classified
Chemical Identifiers
- UNII
- ET3651ZLOU
- CAS number
- Not Available
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment BMI >27 kg/m2 / Obese / Type 2 Diabetes Mellitus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, coated Oral 3150 FIP Liquid Oral Tablet, coated Oral 59.4 mg Tablet Oral 59.4 mg Tablet, coated Oral 300 mg Tablet, coated Oral 25 mg Tablet Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Drug created on April 25, 2018 22:43 / Updated on June 12, 2020 16:53